Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305754
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-03-05
Brief Title:
Sacituzumab Tirumotecan MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor EGFR-Mutated Advanced Nonsquamous Non-small Cell Lung Cancer NSCLC and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors MK-2870-009
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Organization Data
Organization:
Merck Sharp Dohme LLC
Class:
INDUSTRY
Study ID:
2870-009
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck Sharp Dohme LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None